BioSenic S.A. (BIOS.BR)
EUR 0.01
(-5.71%)
EUR 0.01
(-5.71%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -28.77 Million EUR | -1310.0% |
| 2022 | -2.04 Million EUR | 84.21% |
| 2021 | -12.92 Million EUR | -8.25% |
| 2020 | -11.94 Million EUR | -14.14% |
| 2019 | -10.46 Million EUR | 26.42% |
| 2018 | -14.21 Million EUR | -11.5% |
| 2017 | -12.75 Million EUR | 1.82% |
| 2016 | -12.98 Million EUR | 8.17% |
| 2015 | -14.14 Million EUR | -146.67% |
| 2014 | -5.73 Million EUR | -40.57% |
| 2013 | -4.07 Million EUR | -10.57% |
| 2012 | -3.68 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 247.5 Thousand EUR | 0.0% |
| 2024 Q1 | 247.5 Thousand EUR | 106.24% |
| 2023 FY | -28.77 Million EUR | -1310.0% |
| 2023 Q1 | -10.42 Million EUR | -1276.68% |
| 2023 Q2 | -20.84 Million EUR | -100.0% |
| 2023 Q3 | -3.96 Million EUR | 80.96% |
| 2023 Q4 | -3.96 Million EUR | 0.0% |
| 2022 Q4 | -757 Thousand EUR | 0.0% |
| 2022 FY | -2.04 Million EUR | 84.21% |
| 2022 Q3 | -757 Thousand EUR | 76.44% |
| 2022 Q2 | -3.21 Million EUR | 0.0% |
| 2021 Q4 | -6.85 Million EUR | 0.0% |
| 2021 FY | -12.92 Million EUR | -8.25% |
| 2021 Q2 | -6.07 Million EUR | 0.0% |
| 2020 Q4 | -2.11 Million EUR | 0.0% |
| 2020 FY | -11.94 Million EUR | -14.14% |
| 2020 Q2 | -9.83 Million EUR | 0.0% |
| 2019 FY | -10.46 Million EUR | 26.42% |
| 2019 Q2 | -5.53 Million EUR | 0.0% |
| 2019 Q4 | -4.92 Million EUR | 0.0% |
| 2018 Q4 | -5.76 Million EUR | 0.0% |
| 2018 FY | -14.21 Million EUR | -11.5% |
| 2017 FY | -12.75 Million EUR | 1.82% |
| 2016 FY | -12.98 Million EUR | 8.17% |
| 2015 FY | -14.14 Million EUR | -146.67% |
| 2014 Q3 | -1.12 Million EUR | 0.0% |
| 2014 FY | -5.73 Million EUR | -40.57% |
| 2014 Q4 | -1.88 Million EUR | -67.5% |
| 2013 Q4 | -1.34 Million EUR | 0.0% |
| 2013 FY | -4.07 Million EUR | -10.57% |
| 2012 FY | -3.68 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -718.022% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 80.521% |
| Adocia SA | -21.16 Million EUR | -35.989% |
| Aelis Farma SA | -5.07 Million EUR | -466.719% |
| Biophytis S.A. | -17.02 Million EUR | -69.024% |
| Advicenne S.A. | -7.03 Million EUR | -309.302% |
| genOway Société anonyme | 1.56 Million EUR | 1935.829% |
| IntegraGen SA | -171.39 Thousand EUR | -16690.063% |
| Medesis Pharma S.A. | -3.95 Million EUR | -626.811% |
| Neovacs S.A. | -8.74 Million EUR | -229.138% |
| NFL Biosciences SA | -3.74 Million EUR | -668.34% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 36450.087% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -807.552% |
| Sensorion SA | -22.06 Million EUR | -30.433% |
| Theranexus Société Anonyme | -6.82 Million EUR | -321.473% |
| TME Pharma N.V. | -6.73 Million EUR | -327.227% |
| Valbiotis SA | -7.36 Million EUR | -290.581% |
| TheraVet SA | -1.57 Million EUR | -1732.169% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -41.457% |
| argenx SE | -272.91 Million EUR | 89.455% |
| Celyad Oncology SA | -8.44 Million EUR | -240.649% |
| DBV Technologies S.A. | -67.26 Million EUR | 57.22% |
| Galapagos NV | 211.69 Million EUR | 113.594% |
| Genfit S.A. | -28.89 Million EUR | 0.401% |
| GeNeuro SA | -14.75 Million EUR | -95.013% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -87.113% |
| Innate Pharma S.A. | -7.57 Million EUR | -280.159% |
| Inventiva S.A. | -110.42 Million EUR | 73.939% |
| MaaT Pharma SA | -19.71 Million EUR | -45.955% |
| MedinCell S.A. | -25.03 Million EUR | -14.937% |
| Nanobiotix S.A. | -39.7 Million EUR | 27.511% |
| Onward Medical N.V. | -36.18 Million EUR | 20.461% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -758.291% |
| OSE Immunotherapeutics SA | -23 Million EUR | -25.105% |
| Oxurion NV | -18.96 Million EUR | -51.711% |
| Pharming Group N.V. | -9.75 Million EUR | -194.96% |
| Poxel S.A. | -35.09 Million EUR | 17.988% |
| GenSight Biologics S.A. | -26.22 Million EUR | -9.756% |
| Transgene SA | -22.32 Million EUR | -28.887% |
| Financière de Tubize SA | 88.15 Million EUR | 132.646% |
| UCB SA | 343 Million EUR | 108.39% |
| Valneva SE | -101.42 Million EUR | 71.627% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | -1.538% |